ICYMI: Reducing Regulatory Hurdles Can Help Boost Innovation

Featured this week in the Wall Street Journal, columnist Greg Ip discusses how reducing regulatory hurdles to private investment can help boost innovation – specifically as it relates to the biopharmaceutical industry.
One of the biggest challenges facing drug manufacturers “is the staggering cost of development: $2.6 billion on average to bring a new drug to market, once the cost of capital and failed drugs is included, according to Tufts University’s Center for the Study